Indolepropionic acid - ViroPharma Incorporated
Alternative Names: IN-OX1; Indole-3-propionic acid; IPA - ViroPharma Incorporated; OX-1; Oxigon; SHP 22; SHP-622; VP-20629Latest Information Update: 02 Oct 2021
At a glance
- Originator New York University; University of South Alabama
- Developer Intellect Neurosciences; ViroPharma Incorporated
- Class Antidementias; Indoles; Neuroprotectants; Propionic acids; Small molecules
- Mechanism of Action Amyloid inhibitors; Antioxidants; Chelating agents; Free radical scavengers; Protein aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Friedreich's ataxia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Friedreich's ataxia in USA (PO, Capsule)
- 01 Jul 2015 Shire ViroPharma completes a phase I trial in Friedreich's ataxia in USA (NCT01898884)
- 11 Mar 2014 ViroPharma is now called Shire ViroPharma